Phase 2 clinical trial data published in the New England Journal of Medicine (Jastreboff et al., 2023) reported potentially significant effects on body weight reduction and glycaemic control
This injectable medication works by enhancing insulin secretion in response to meals, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system pathways
All of these terms refer to the same investigational compound
2 Incretin therapies currently available in Australia Dulaglutide, liraglutide and semaglutide, which are synthetic versions of human GLP-1, and tirzepatide, a single molecule dual GLP-1 and GIP receptor coagonist, are available in Australia
Lieferung in 34 Werktagen Vorteile : Kann anregend wirken
Reddy AC, Lokesh BR